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Herpesviruses are a leading cause of 
human viral disease. There are eight 
distinct herpesviruses known to cause a 
range of debilitating acute and recurrent 
diseases in humans [1–3]. Examples include 
HSV-1, which causes cold sores and geni-
tal lesions; hCMV, which is associated 
with glandular fever and a range of con-
ditions in immunocompromised patients 
and congenitally infected newborns; and 
Kaposi’s sarcoma-associated herpesvirus 
(KSHV), which is an oncogenic herpes-
virus associated with commonly fatal 
malignancies in immuno compromised 
individuals. Currently, drugs in clinical 
use for the treatment of herpesvirus infec-
tions are inhibitors of herpesvirus DNA 
polymerases. These nucleotide, nucleo-
side and pyrophosphate analogs are effec-
tive against a number of herpesviruses, 
although drug-resistant strains are emerg-
ing in immunocompromised patients [4]. 
Moreover, poor efficacy has been reported 
against the oncogenic herpesvirus subfam-
ily [5]. Consequently, there is an urgent 
need for the continued development of 
antiherpesvirus drugs, particularly target-
ing oncogenic  herpesviruses.
Herpesviruses are among the most 
common viruses found in humans. Once 
an individual has become infected by a 
herpesvirus the infection persists, lead-
ing to recurrent outbreaks of disease. 
Herpesviruses have a unique biphasic life 
cycle, comprising the persistent dormant 
infection known as the latent state, which 
can be spontaneously reactivated to initi-
ate the lytic replication cycle. During lytic 
replication infectious virions are produced, 
which, in the majority of cases, spread the 
virus infection, leading to the character-
istic disease associated with the herpes-
virus. Notably, inhibiting the lytic stages 
of the herpesvirus life cycle is a key goal for 
efficacious herpesvirus-targeted therapeu-
tics. Such inhibition, while not eradicat-
ing the latent lifelong infection, will treat 
the pathogenic symptoms associated with 
 herpesvirus infection.
Like all viruses, herpesviruses manipu-
late and utilize the host cell’s machinery to 
enhance their own replication to produce 
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infectious virions, resulting in virus spread and 
disease. One such example, essential for herpes-
virus replication, is the interaction of a conserved 
family of herpesvirus-encoded RNA-binding 
proteins with a large cellular multiprotein com-
plex termed TREX [6–10]. Human herpesviruses 
utilize multiple components of hTREX to sta-
bilize and thus preferentially promote nuclear 
export of herpesviral mRNAs [11]. Specifically, 
hTREX serves as a binding platform for the cell-
ular mRNA export factor Nxf1 on herpesvirus 
mRNAs forming a stable and export competent 
viral ribonucleoprotein particle.
The recent discovery that a core component 
of hTREX, the RNA helicase UAP56, remod-
els the hTREX complex in an ATP-dependent 
manner [12,13] has given rise to the idea that 
the interaction of hTREX with herpesvirus-
encoded adapter proteins might also be regu-
lated in an ATP-dependent manner. This strat-
egy provided an especially attractive option for 
inhibition of herpesvirus replication, as target-
ing of the ATPase function of viral and cell-
ular RNA helicases has already been explored, 
showing selective pharmacological targeting is 
possible [14–16]. Notably, the targeting of a cell-
ular RNA helicase would also reduce the risk 
of viral resistance and would have potential 
 pan-herpesvirus activity.
In a recent publication, the novel approach 
of targeting hTREX to prevent herpesvirus 
lytic replication is demonstrated [17]. Using 
co-immunoprecipitation assays we first iden-
tif ied that ATP-dependent remodeling of 
hTREX affects the interaction of the KSHV-
encoded adapter protein, known as ORF57, 
independently of the native hTREX complex. 
Specifically, formation of the complete hTREX 
required binding of ATP by UAP56. However, 
this ATP-bound state was insufficient to recruit 
the KSHV ORF57 protein. Here, a further 
ATP hydrolysis event was essential to mediate 
the ORF57–hTREX interaction. We therefore 
speculated that a small molecule inhibitor 
disrupting UAP56-mediated ATP hydroly-
sis would allow an assembly of endogenous 
hTREX, but prevent KSHV ORF57 recruit-
ment. This, in turn, would prevent herpes-
virus viral ribonucleoprotein particle forma-
tion and subsequently viral lytic replication. 
Importantly, as hTREX recruitment is not spe-
cific to KSHV but conserved in other human 
herpesviruses, any inhibitory compound 
targeting the activity of the cellular UAP56 
protein should also inhibit lytic replication in 
a  potentially pan-herpesvirus fashion.
A virtual high-throughput screening approach 
was therefore used to identify potential inhibi-
tors of UAP56 ATPase activity. Following 
in vitro screening, the prioritized hit compound, 
CCT018159, was shown to specifically disrupt 
the interaction of multiple herpesviral adapter 
proteins, KSHV ORF57, HSV-1 ICP27 and 
hCMV pUL69, with UAP56, without disrupt-
ing endogenous hTREX assembly. Furthermore, 
the compound inhibited KSHV viral mRNA, 
but not cellular bulk mRNA nuclear export. 
Moreover, CCT018159 relieved cells from 
ORF57-imposed hTREX sequestration, result-
ing in reduced KSHV DNA replication and 
infectious virion production. Similar inhibition 
was also observed for HSV-1 and hCMV lytic 
replication and infectious virion production.
Our results suggest that a clear therapeutic 
window, which inhibits herpesvirus replication 
with limited host cell toxicity, can be achieved. 
However, CCT018159 is also a known HSP90 
inhibitor [18], and although we could effec-
tively inhibit UAP56 activity within HSP90 
functional parameters, CCT018159-mediated 
inhibition of HSP90 at higher concentra-
tions restricted the therapeutic window. This 
highlights the need for further generation of 
a more targeted UAP56 inhibitory compound 
with reduced off-target effects. Here, future 
medicinal chemistry approaches will endeavor 
to increase the affinity of CCT018159-related 
compounds for UAP56, as well as improve its 
complex pharmacokinetics, which include a 
relatively high metabolic turnover, and reduce 
the above-mentioned HSP90-related off-target 
effects. However, the identification and subse-
quent characterization of CCT018159 against 
KSHV, HSV-1 and hCMV has shown that it is 
possible to target the hTREX complex to inhibit 
herpesvirus lytic replication. Although we are 
still several generations from a feasible drug in 
clinical use, this can be seen as a starting point 
for lead compound development.
One obvious limitation of this novel target-
ing approach to treat herpesvirus-related diseases 
includes, for example, EBV latency-associated 
lymphomas and carcinomas, and other diseases 
associated with herpesvirus latent gene expres-
sion. Interestingly, however, UAP56 has also 
been implicated in mRNA processing of other 
distinct groups of viruses, such as influenza 
A virus and HBV. While influenza A virus is 
“…the identification and 
subsequent 
characterization of 
CCT018159 against KSHV, 
HSV-1 and hCMV has 
shown that it is possible to 
target the hTREX complex 
to inhibit herpesvirus lytic 
replication.”
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believed to require a virally encoded adapter 
protein to bridge the interaction between viral 
mRNA and hTREX [19], HBV employs a spe-
cial cellular adapter protein [20]. This allows for 
the intriguing idea that targeting hTREX ATP-
dependent remodeling may also be effective at 
inhibiting not only herpesviruses, but other 
 distinct classes of viruses.
In summary, our study has highlighted a 
novel approach to target herpesvirus lytic rep-
lication and potentially other human patho-
gens through inhibition of the hTREX com-
plex. While the identified inhibitor is only a 
hit compound, which now requires a lengthy 
hit-to-lead development process to produce 
a compound fit for clinical use, the findings 
are extremely encouraging, as they demon-
strate movement toward a new  generation of 
 antiherpesvirus drugs.
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